Fosfomycin susceptibility among extended-spectrum-β-lactamase-producing Escherichia coli in Nottingham, UK

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 5, 2010, Pages 1076-1077

  Chislett, R J ^a   White, G ^a   Hills, T ^a   Turner, D P J ^a,b  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ESBLs; Monuril; Urinary tract infections

Indexed keywords

BETA LACTAMASE CTX M; FOSFOMYCIN; FOSFOMYCIN TROMETAMOL; ANTIINFECTIVE AGENT; BETA LACTAMASE; ESCHERICHIA COLI PROTEIN;

AGAR DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DISK DIFFUSION; ESCHERICHIA COLI; LETTER; NONHUMAN; UNITED KINGDOM; AGED; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; ESCHERICHIA COLI INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; URINARY TRACT INFECTION;

AGED; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FOSFOMYCIN; GREAT BRITAIN; HUMANS; MICROBIAL SENSITIVITY TESTS; URINARY TRACT INFECTIONS;

EID: 77953718840     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq051     Document Type: Letter

References (9)

1. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK. J Antimicrob Chemother 2005; 56: 451-4.
2. Falagas ME, Karageorgopoulos DE. Extended-spectrum b-lactamaseproducing organisms. J Hosp Infect 2009; 73: 345-54.
3. Thomas K, Weinbren MJ, Warner M et al. Activityofmecillinamagainst ESBL producers in vitro. J Antimicrob Chemother 2006; 57: 367-8.
4. Wootton M, Walsh TR, Macfarlane L et al. Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 2010; 65: 79-81.
5. Falagas ME, Giannopoulou KP, Kokolakis GN et al. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin Infect Dis 2008; 46: 1069-77.
6. Sádaba-Díaz de Rada B, Azanza-Perea JR, García-Quetglas E et al. Fosfomycin trometamol: multiple-dose regimen for the treatment of lower urinary tract infections. Enferm Infecc Microbiol Clin 2006; 24: 546-50.
7. Andrews JM for the BSAC Working Party on Susceptibility Testing. BSAC standardized disc susceptibility testing method (version 8). J Antimicrob Chemother 2009; 64: 454-89.
8. Health Protection Agency. Laboratory detection and reporting of bacteria with extended spectrum β-lactamases. Health Protection Agency Standard Method QSOP 51, issue no. 2.2, 2008; 1-13. http://www.hpa-standardmethods.org.uk/documents/qsop/pdf/qsop51.pdf (31 January 2010, date last accessed).
9. Falagas ME, Maraki S, Karageorgopoulos DE et al. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents 2010; 35: 240-3.